Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Reassessing design and analysis of two-colour microarray experiments using mixed effects models.

Rosa GJ, Steibel JP, Tempelman RJ.

Comp Funct Genomics. 2005;6(3):123-31. doi: 10.1002/cfg.464.

2.

Prospective study of wide excision alone for ductal carcinoma in situ of the breast.

Lagios MD, Page DL, Silverstein MJ.

J Clin Oncol. 2006 Aug 10;24(23):3809-11; author reply 3811-2. No abstract available.

PMID:
16896011
3.

Prospective study of wide excision alone for ductal carcinoma in situ of the breast.

Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL.

J Clin Oncol. 2006 Mar 1;24(7):1031-6. Epub 2006 Feb 6.

PMID:
16461781
4.

Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast?

Solin LJ.

J Clin Oncol. 2006 Mar 1;24(7):1017-9. Epub 2006 Feb 6. No abstract available.

PMID:
16461780
5.

Towards a single cell cancer diagnosis. Multimodal and monocellular measurements of markers and morphology (5M).

Böcking A, Stockhausen J, Meyer-Ebrecht D.

Cell Oncol. 2004;26(1-2):73-9. Review. No abstract available.

6.

Ductal carcinoma in situ, complexities and challenges.

Leonard GD, Swain SM.

J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. Review.

PMID:
15199110
7.

Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate.

Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW.

Clin Cancer Res. 2004 May 15;10(10):3465-73.

8.

Morphometrical malignancy grading is a valuable prognostic factor in invasive ductal breast cancer.

Kronqvist P, Kuopio T, Jalava P, Collan Y.

Br J Cancer. 2002 Nov 18;87(11):1275-80.

9.

Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis.

Wärnberg F, Casalini P, Nordgren H, Bergkvist L, Holmberg L, Ménard S.

Breast Cancer Res Treat. 2002 Jun;73(3):215-21.

PMID:
12160327
10.

In situ duct carcinoma of the breast: clinical and histopathologic factors and association with recurrent carcinoma.

Miller NA, Chapman JA, Fish EB, Link MA, Fishell E, Wright B, Lickley HL, McCready DR, Hanna WM.

Breast J. 2001 Sep-Oct;7(5):292-302.

PMID:
11906438
11.
12.
13.

Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.

Leong AS, Sormunen RT, Vinyuvat S, Hamdani RW, Suthipintawong C.

Am J Clin Pathol. 2001 May;115(5):709-18.

PMID:
11345835
14.

Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.

Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):249-59.

15.

Nuclear cytometric changes in breast carcinogenesis.

Mommers EC, Poulin N, Sangulin J, Meijer CJ, Baak JP, van Diest PJ.

J Pathol. 2001 Jan;193(1):33-9.

PMID:
11169513
16.

Outcomes and factors impacting local recurrence of ductal carcinoma in situ.

Lagios MD, Silverstein MJ.

Cancer. 2000 Dec 1;89(11):2323-5. No abstract available.

PMID:
11147605
17.

Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma.

Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N.

Cancer. 1999 Aug 1;86(3):429-38.

PMID:
10430251
18.

Ductal Carcinoma In Situ of the Breast: Controversial Issues.

Silverstein MJ.

Oncologist. 1998;3(2):94-103.

19.

Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ.

Sneige N, Lagios MD, Schwarting R, Colburn W, Atkinson E, Weber D, Sahin A, Kemp B, Hoque A, Risin S, Sabichi A, Boone C, Dhingra K, Kelloff G, Lippman S.

Hum Pathol. 1999 Mar;30(3):257-62.

PMID:
10088542
20.

Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.

Fish EB, Chapman JA, Miller NA, Link MA, Fishell E, Wright B, McCready DR, Hiraki GY, Ross TM, Hanna WM, Lickley HL.

Ann Surg Oncol. 1998 Dec;5(8):724-32.

PMID:
9869520

Supplemental Content

Support Center